Category - Developments

Developments

Magenta, Dianthus in merger agreement

Magenta Therapeutics (NASDAQ:MGTA) and closely-held Dianthus Therapeutics entered into a definitive merger agreement to combine the companies in an all-stock transaction that is expected to close in the third quarter of...

May 3, 2023

Developments

NeuroSense posts positive preliminary PD biomarker data

NeuroSense Therapeutics (NASDAQ:NRSN) reported positive preliminary results from a novel biomarker study conducted to evaluate the potential of its combination platform therapy for the treatment of Parkinson’s...

May 2, 2023

Developments

Profound Medical’s TULSA procedure featured at AUA

Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA procedure was featured in four presentations at the American Urological Association (AUA) annual meeting that reinforced its safety, efficacy and durability, further...

May 1, 2023

Developments

Kiora RP treatment seen restoring visual function in blind patients

Kiora Pharmaceuticals (NASDAQ:KPRX) presented preliminary results from an ongoing clinical trial, showing that its investigational drug, KIO-301, has the potential to restore light perception in patients who are blind...

April 28, 2023

Developments

Avidity posts positive Phase 1/2 topline data in myotonic dystrophy 1

Avidity Biosciences (NASDAQ:RNA) reported positive topline data from the Phase 1/2 MARINA clinical trial of AOC 1001 for the treatment of myotonic dystrophy type 1 (DM1), an underrecognized, progressive and often fatal...

April 28, 2023

Developments

SAB posts positive Phase 3 results in high-risk COVID-19 patients

SAB Biotherapeutics (NASDAQ:SABS) reported positive top-line results from the Phase 3 National Institutes of Health’s ACTIV-2 clinical trial that assessed SAB-185 in non-hospitalized people with COVID-19 who were at...

April 26, 2023

Developments

Morphic posts positive cohort data in ulcerative colitis

Morphic Therapeutic (NASDAQ:MORF) reported positive topline data from the main cohort of the open-label EMERALD-1 Phase 2a study of MORF-057, an oral small molecule inhibitor of the α4β7 integrin, in adults with...

April 25, 2023

Developments

Lyra restarts Phase 3 trial in chronic rhinosinusitis

Lyra Therapeutics (NASDAQ:LYRA) resumed screening and enrollment in ENLIGHTEN II, its second Phase 3 clinical trial of LYR-210 in patients with chronic rhinosinusitis (CRS). LYR-210 is a bioresorbable nasal implant...

April 25, 2023

Developments

Blue Water Vaccines changes name to Blue Water Biotech

Blue Water Vaccines changed its corporate name to Blue Water Biotech, following its recent acquisition of ENTADFI, an FDA-approved treatment for benign prostatic hyperplasia, which has begun Blue Water’s transition into...

April 25, 2023

Developments

Lantheus, POINT get FDA fast track for mCRPC

The FDA granted Lantheus Holdings (NASDAQ:LNTH) and POINT Biopharma (NASDAQ:PNT) fast track designation for 177Lu-PNT2002 for the treatment of metastatic castration resistant prostate cancer (mCRPC). PNT2002 is an...

April 24, 2023

Category - Developments

Subscribe